Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5206MR)

This product GTTS-WQ5206MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5206MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7032MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ3886MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ5900MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ2129MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ5907MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ11774MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ2559MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ7972MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GX-17
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW